Johnson & Johnson (NYSE:JNJ) Shares Acquired by M&G Plc

M&G Plc increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 47.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 288,289 shares of the company’s stock after acquiring an additional 92,762 shares during the quarter. M&G Plc’s holdings in Johnson & Johnson were worth $42,090,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the company. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson in the first quarter valued at approximately $31,000. Keener Financial Planning LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at $40,000. WFA Asset Management Corp increased its holdings in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in Johnson & Johnson during the fourth quarter worth approximately $45,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $1.49 during trading hours on Tuesday, hitting $158.39. 9,194,576 shares of the company were exchanged, compared to its average volume of 7,368,586. The business has a 50-day moving average of $151.41 and a 200-day moving average of $153.07. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.60. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $381.19 billion, a price-to-earnings ratio of 9.81, a P/E/G ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. During the same quarter last year, the business earned $2.80 EPS. The business’s revenue was up 4.3% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.13%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Analyst Ratings Changes

A number of research firms have weighed in on JNJ. TD Securities cut their price objective on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. The Goldman Sachs Group decreased their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Sanford C. Bernstein raised their price objective on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a report on Tuesday, July 30th. Finally, StockNews.com downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Thursday, August 8th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.